专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009038659A3 ORGANICALLY MODIFIED SILICA NANOPARTICLES WITH COVALENTLY INCORPORATED PHOTOSENSITIZERS FOR DRUG DELIVERY IN PHOTODYNAMIC THERAPY 审中-公开
标题翻译：有机改性二氧化硅纳米颗粒与光合动力疗法中药物递送的共同合成光敏剂
公开(公告)号：WO2009038659A3
公开(公告)日：2009-09-03
申请号：PCT/US2008010608
申请日：2008-09-11
申请人： HEALTH RESEARCH INC , UNIV NEW YORK STATE RES FOUND , PANDEY RAVINDRA , GOSWAMI LALIT , OSEROFF ALLAN , MORGAN JANET , PRASAD PARAS , BERGEY EARL , OHULCHANSKYY TYMISH , ROY INDRAJIT
发明人： PANDEY RAVINDRA , GOSWAMI LALIT , OSEROFF ALLAN , MORGAN JANET , PRASAD PARAS , BERGEY EARL , OHULCHANSKYY TYMISH , ROY INDRAJIT
IPC分类号： B23B9/04
CPC分类号： A61K49/0093 , A61K41/0071 , A61K49/0036 , A61K49/1824 , A61K51/1244 , B82Y5/00
摘要： Nanoparticles containing covalently linked photosensitizer molecules that overcome the drawback of premature release and thus enhance the outcome of PDT. [Silica-based nanoparticles are provided containing at least one covalently linked photosensitizer. The photosensitizer is preferably a tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides, and phthalocyanines, naphthanocyanines with and without fused ring systems and derivatives of all the above. The nanoparticle may also include covalently linked imaging agents, e.g. radionuclides, magnetic resonance (MR) and fluorescence imaging agents. The imaging agents and photosensitizers may be at a periphery (surface) of the nanoparticles to increase efficiency. Target-specific nanoparticles may be provided by incorporating biotargeting molecules such as specific antibodies at the surface that react with particular ligands to obtain target specificity. Diagnostic agents may be present in the antibody in addition to imaging agents and tumor specific photosensitizers.
摘要翻译：含有共价连接的光敏剂分子的纳米颗粒克服了过早释放的缺点，从而增强了PDT的结果。提供含有至少一种共价连接的光敏剂的基于二氧化硅的纳米颗粒。光敏剂优选为与卟啉，二氢卟酚，细菌二氢卟酚，苯并二氢卟酚，苯并卟啉衍生物，包括焦偏磷酸盐和酞菁的脱镁叶绿素，具有和不具有稠环体系的萘磺酸以及所有上述衍生物有关的四吡咯基化合物。纳米颗粒还可以包括共价连接的成像剂，例如。放射性核素，磁共振（MR）和荧光成像剂。成像剂和光敏剂可以在纳米颗粒的外围（表面）上以提高效率。可以通过在与特定配体反应的表面上并入生物靶向分子例如特异性抗体以获得靶特异性来提供靶特异性纳米颗粒。除成像剂和肿瘤特异性光敏剂之外，诊断剂可存在于抗体中。

2. 发明申请

WO2008048205A2 METHOD FOR DELIVERING HYDROPHOBIC DRUGS VIA NANOCRYSTAL FORMULATIONS 审中-公开
标题翻译：通过纳米晶体制剂递送疏水性药物的方法
公开(公告)号：WO2008048205A2
公开(公告)日：2008-04-24
申请号：PCT/US2006023886
申请日：2006-06-20
申请人： UNIV NEW YORK STATE RES FOUND , HEALTH RESEARCH INC , PRASAD PARAS N , PUDAVAR HARIDAS E , BABA KOICHI , ROY INDRAJIT , OHULCHANSKYY TYMISH , PANDEY RAVINDRA K , OSEROFF ALLAN
发明人： PRASAD PARAS N , PUDAVAR HARIDAS E , BABA KOICHI , ROY INDRAJIT , OHULCHANSKYY TYMISH , PANDEY RAVINDRA K , OSEROFF ALLAN
IPC分类号： A61K31/555 , A61K9/14 , A61K31/409
CPC分类号： A61K9/14 , A61K9/146 , A61K31/409 , A61K31/4745 , A61K31/555 , A61K49/0021 , A61K49/0032 , A61K49/0036 , A61K49/0054 , A61K49/0067 , G01N33/5005 , G01N33/52
摘要： This invention provides nanocrystals or polymer doped nanocrystals of hydrophobic drug molecules as stably dispersed in an aqueous system which are prepared without stabilizers like surfactants and the like. In one embodiment, the drug is a tetra-pyrrole compound. An example is the hydrophobic photosensitizing anticancer drug 2-devinyl-2-(l - hexyloxyethyl) pyropheophorbide (HPPH). Pharmaceutical compositions comprising nanocrystals or polymer doped nanocrystals of hydrophobic drugs can be used for therapeutic purposes. For example pyropheophorbides such as HPPH can be used for photodynamic therapy. Drug efficacy of these nanocrystals were found to be comparable with that of same drug formulated in conventional delivery vehicles under in vitro and in vivo conditions.
摘要翻译：本发明提供了稳定分散在水性体系中的疏水性药物分子的纳米晶体或聚合物掺杂的纳米晶体，其不经过稳定剂如表面活性剂等制备。在一个实施方案中，药物是四吡咯化合物。一个例子是疏水性光敏抗癌药2-脱乙烯基-2-（1-己氧基乙基）焦脱镁叶绿素（HPPH）。包含纳米晶体或疏水性药物的聚合物掺杂纳米晶体的药物组合物可用于治疗目的。例如焦磷偏磷酸盐如HPPH可用于光动力疗法。发现这些纳米晶体的药物功效与在体外和体内条件下在常规递送载体中配制的相同药物相当。

3. 发明申请

WO2009105210A3 B RING REDUCED-D RING OXIDIZED TETRAPYROLLIC PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY AND TUMOR IMAGING 审中-公开
标题翻译：用于光化学治疗和肿瘤成像的B环减少D环氧化的光致变色光敏剂
公开(公告)号：WO2009105210A3
公开(公告)日：2009-12-30
申请号：PCT/US2009001030
申请日：2009-02-19
申请人： HEALTH RESEARCH INC , PANDEY RAVINDRA K , LIU CHAO , DOBHAL MAHABEER , POTTER WILLIAM , MORGAN JANET , OSEROFF ALLAN
发明人： PANDEY RAVINDRA K , LIU CHAO , DOBHAL MAHABEER , POTTER WILLIAM , MORGAN JANET , OSEROFF ALLAN
IPC分类号： A01N55/02
CPC分类号： C07D487/22
摘要： Tetrapyrollic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl36H2O to oxidize the D ring and separating the resulting organic layer and drying.
摘要翻译：具有A，B，C和D环并且具有还原的B环和氧化的D环的四味光敏剂和显影剂化合物。化合物优选具有至少95％的纯度，并且优选具有在C环的最接近D环的不饱和碳原子和C和D环之间的不饱和碳原子连接的稠合体系。本发明还包括通过用B和D环氧化的四元醇化合物开始制备化合物百分之九十五以上的方法，并将其溶解在卤代烃溶剂中，并用足够的FeCl 3·6H 2 O的硝基烷烃溶液处理以氧化D环并分离所得有机层并干燥。

4. 发明申请

WO2008008215A3 METHOD FOR ENHANCING PDT EFFICACY USING A TYROSINE KINASE INHIBITOR 审中-公开
标题翻译：使用酪氨酸激酶抑制剂增强PDT效率的方法
公开(公告)号：WO2008008215A3
公开(公告)日：2008-09-04
申请号：PCT/US2007015263
申请日：2007-06-29
申请人： HEALTH RESEARCH INC , PANDEY RAVINDRA K , OSEROFF ALLAN , MORGAN JANET , ZHENG XIANG , WEIGUO LIU
发明人： PANDEY RAVINDRA K , OSEROFF ALLAN , MORGAN JANET , ZHENG XIANG , WEIGUO LIU
IPC分类号： A61K31/409
CPC分类号： A61K31/409 , A61K41/0061 , A61K41/0071
摘要： A method for treating hyperproliferative tissue in a mammal which tissue expresses ABCG2 including the steps of: a) systemically introducing from about 100 to about 1000 mg/kg of body weight of a tyrosine kinase inhibiting compound into the mammal; b) within from about 0.5 to about 24 hours after the introducing in step a) systemically introducing from about 0.05 to about 0.5 µmol per kilogram of body weight of a tumor avid photosensitizing compound, that acts as a substrate for ABC family transport protein, ABCG2 and that has a preferential light absorbance frequency; and c) exposing the hyperproliferative tissue to light at a fluence of from about 50 to about 150 J/cm 2 delivered at a rate of from about 5 to about 25 mW/cm 2 at the light absorbance frequency. The photosensitizing compound is preferably a tetrapyrollic photosensitizer compound where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pheophorbide including pyropheophorbides, purpurinimide, or bacteriopurpurinimide and derivatives thereof; provided that, the photosensizing compound is not a meso-tetra (3-hydroxyphenyl) derivative, is not a saccharide derivative and is not a hematoporphyrin.
摘要翻译：一种用于治疗组织表达ABCG2的哺乳动物的过度增殖组织的方法，包括以下步骤：a）将约100至约1000mg / kg体重的酪氨酸激酶抑制化合物全身引入哺乳动物; b）在步骤a）中引入后约0.5至约24小时内，全身引入约0.05至约0.5μmol/千克体重的肿瘤avid光敏化合物，其作为ABC家族转运蛋白ABCG2的底物并具有优先吸光度频率; 并且c）将过度增殖组织以约5至约25mW / cm 2的速率递送的约50至约150J / cm 2的能量密度曝光， SUP>在吸光度频率。光敏化合物优选为四级光敏剂化合物，其中四味化合物是二氢卟酚，细菌二氢卟酚，卟啉，含有偏高双歧杆菌，嘌呤酰亚胺或嘌呤嘌呤酰亚胺及其衍生物的脱镁叶绿素; 光敏化合物不是内消旋 - 四（3-羟基苯基）衍生物，不是糖衍生物，不是血卟啉。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式